Precision Optics (POCI) Q4 2025: Systems Manufacturing Set for 75% Growth as Margin Recovery Takes Hold
Precision Optics exited fiscal 2025 with record quarterly revenue, but margin pressure from production ramp and tariffs defined the year’s bottom line. Management’s 2026 outlook calls for a 75% surge in systems manufacturing and a 12-point gross margin rebound, backed by long-term contracts and a deepening engineering pipeline. The company’s operational investments and customer-backed pricing resets position POCI to capitalize on scaling volumes, though execution on yield and cost remains the critical watchpoint heading into the new year.
Summary
- Production Ramp: Two major programs transitioned from development to production, anchoring revenue visibility.
- Margin Inflection: Tariff pass-throughs and pricing resets set the stage for gross margin recovery in fiscal 2026.
- Operational Scaling: Facility expansion and leadership hires target higher-volume, more efficient manufacturing execution.
Performance Analysis
Precision Optics delivered its highest quarterly revenue in company history, reaching $6.2 million in Q4, which annualizes at a $25 million run rate. The company’s transformation from an engineering-centric to a manufacturing-driven business is now visible, with production revenue accounting for the majority of growth. The two flagship programs—a complex aerospace assembly and a single-use cystoscope for surgical robotics—were the primary contributors, with the former’s revenue climbing from $300,000 in Q1 to nearly $2 million in Q4 and backlog now at $9 million.
However, gross margin deterioration was the defining challenge of the year, falling to 18% for fiscal 2025 from 30% the prior year. The cystoscope program, while scaling, operated at zero or negative gross margin due to yield issues, higher labor, and substantial tariff costs. Engineering revenue, which carries higher margins, dipped as resources shifted to support production troubleshooting. With renegotiated pricing (up 24%), tariff reimbursement agreements, and targeted process improvements, management expects gross margin to rebound to 30% in 2026, with the majority of improvement weighted to the back half of the year.
- Revenue Mix Shift: Production revenue nearly doubled YoY, while engineering revenue softened as pipeline programs converted to manufacturing.
- Tariff Headwinds: Q4 tariff costs alone reduced gross margin by 3 percentage points, but customer pass-throughs are now in place.
- Operating Leverage: SG&A and R&D increased modestly, reflecting investments in talent and the Unity platform, but scaling volumes are expected to drive EBITDA recovery in fiscal 2026.
The company ended the fiscal year with $1.8 million in cash and $1.9 million in debt, and is seeking additional debt capital to support ongoing expansion.
Executive Commentary
"We just finished the fiscal year with the highest quarterly revenue in our company's history. The $6.2 million fourth quarter puts us at an annualized run rate of approximately $25 million, and the underlying drivers of this increase are sustainable into the foreseeable future."
Dr. Joe Forkey, Chief Executive Officer
"On the surface, [flat annual revenue] masks the trend in the transformation of our more engineering-focused business to a more rapidly scaling manufacturing enterprise. We now project fiscal 2026 revenues to reach $25 million. This growth is being driven by continued expansion of our systems manufacturing business as our backlog and production demand continues to increase."
Wayne Cole, Chief Financial Officer
Strategic Positioning
1. Transition to Scaled Manufacturing
POCI is pivoting from niche engineering to high-volume manufacturing, with systems manufacturing revenue expected to increase 75% in fiscal 2026. This shift is anchored by long-term production contracts in aerospace and medical devices, each with minimum annual commitments, providing multi-year revenue visibility and a foundation for operational leverage.
2. Margin Recovery Through Pricing and Process
Gross margin recovery is central to the 2026 thesis. The company has renegotiated pricing (up 24%) and secured tariff reimbursement from its largest medical device customer. Simultaneously, process improvements and design tweaks are underway to address yield and labor inefficiencies, with full benefit expected by Q3 2026.
3. Engineering Pipeline and the Unity Platform
The engineering pipeline is rebounding as resources are redeployed from production troubleshooting back to new development. The Unity platform, POCI’s modular imaging architecture, is driving customer acquisition and is expected to move two to three programs into production annually over the next two years, sustaining future growth beyond the current anchor programs.
4. Operational Investments and Leadership Upgrades
Facility expansions in Massachusetts and Maine, along with the hiring of a new COO with deep medical device experience, reflect a commitment to building infrastructure and leadership for higher-scale operations. These moves are designed to support both immediate production ramp and long-term manufacturing efficiency.
Key Considerations
Fiscal 2025 marked a strategic inflection point, with record revenue but pronounced margin and execution challenges. The company’s ability to translate backlog and production ramp into sustainable profitability will define the next phase.
Key Considerations:
- Backlog Strength: $9 million backlog in aerospace and growing medical device demand underpin 2026 revenue visibility.
- Margin Sensitivity: Tariff pass-throughs and pricing resets are critical, but yield improvements must materialize to meet margin targets.
- Engineering Resource Allocation: Redeployment from production to new development is underway, supporting pipeline replenishment and future production transitions.
- Operational Complexity: Scaling from small-batch to high-volume production introduces risks in process control and cost management.
- Capital Requirements: Cash and debt levels are tight, with additional debt funding required to support expansion and working capital needs.
Risks
Execution risk remains elevated as POCI scales production and implements process improvements. Delays in yield recovery, customer ramp rates, or engineering pipeline conversion could pressure margin and cash flow. The company’s reliance on a few large programs heightens concentration risk, while ongoing tariff and supply chain volatility could reintroduce cost headwinds if customer reimbursement agreements are not fully realized or if new tariffs emerge.
Forward Outlook
For Q1 and fiscal 2026, Precision Optics guided to:
- Approximately $25 million in revenue for fiscal 2026, matching the Q4 annualized run rate
- Gross margin recovery to roughly 30% for the year, with stronger improvement in the back half
For full-year 2026, management maintained guidance:
- Systems manufacturing revenue growth of 75% YoY
- Adjusted EBITDA returning to positive territory, targeting $0.5 million
Management emphasized:
- Margin improvement hinges on yield recovery and tariff reimbursement
- Engineering pipeline is set to deliver two to three new production programs annually
Takeaways
Precision Optics’ transformation from engineering services to scaled manufacturing is underway, but the next year will test its operational maturity and pricing power. The company’s backlog and customer commitments provide a revenue floor, but margin recovery and execution on cost remain the gating factors for sustainable profitability.
- Scaling Leverage: Systems manufacturing is now the primary growth engine, but must deliver on cost and yield to achieve margin targets.
- Margin Watch: Tariff and pricing resets provide near-term relief, but sustainable gains depend on process execution and engineering pipeline conversion.
- Pipeline Conversion: Watch for new programs moving from development to production as a signal of future revenue durability and diversification.
Conclusion
Precision Optics exits fiscal 2025 with record revenue and a solid production backlog, but faces a critical year of operational execution as it targets a return to profitability and higher margins. The path to sustainable growth and leverage is clear, though not without execution risk as the company scales its manufacturing ambitions.
Industry Read-Through
POCI’s experience highlights the operational and margin challenges that come with scaling from niche engineering to volume manufacturing, a pattern seen across medtech and advanced manufacturing sectors. Tariff pass-throughs and customer-backed pricing resets are increasingly necessary for small suppliers facing global cost volatility. The emphasis on modular platforms like Unity reflects a broader industry trend toward platformization to accelerate product development and customer acquisition. Investors should watch for similar margin and scaling dynamics at other contract manufacturers and medtech suppliers as device OEMs push for innovation and supply chain resilience.